Hello, this is HEAL - Premium ThemeForest Health Care Theme. After purchase you may change this text on whatever you want.
Boards
Board of directors
Pr Etienne Baulieu – MD, PhD, President
Member of the US and French Academies of Sciences
Brought RU486 to the market
Deciphered DHEA properties
Lasker Award winner and numerous other prestigious awards
Brings high-level, lifelong expertise in Neurosteroids
Brings outstanding vision of medical development
Dr Isabelle Villey – PhD, MBA, Chief Executive Officer
Former INSERM researcher & vice-director of the Vision Institute
Former COO of a start-up company (ophtha device)
Brings alliance of business & science
Dr Nicolas Froger – PhD, Head Of Preclinical Research
Former group leader at the Vision Institute
Brings knowledge and know-how in Neurotraumatology and Depression
Board of advisors
International tier-top Scientific Advisors
Pr Robin FRANKLIN, Neurobiologist,
Director of the Cambridge Stem Cell Institute, Cambridge University, UK ;
Pr Barbara MASON, Neurobiologist,
Director of the Scripps Alcohol Human Research Laboratory, NIH/USA;
Pr Philippe FOSSATI, Psychiatrist
Chief of Psychiatry unit, Depression/Treatment Resistant Depression service, La Salpêtrière Hospital, Paris, France;
Pr Raphaël GAILLARD, Psychiatrist,
Chief of Psychiatry unit, Depression/Treatment Resistant Depression/ Addiction service, Ste Anne Hospital, Paris, France.
Pr Pierre BLIER, Psychiatrist
Chief of Psychiatric unit, The Royal Hospital, Toronto, Canada;
Regulatory and Drug Development
Dr Denis RAVEL, PhD in metabolism,
ex-SERVIER, ex-Bayer, >30 years experience in bringing neurocompounds to Phase 3 and licensing
Contact
CHU Bicêtre, Batiment Pincus,
80 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France.